ArticleMediators of inflammation2012
Expression of PAFR as part of a prosurvival response to chemotherapy: a novel target for combination therapy in melanoma.
Article in Mediators of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- Nucleic acid nanobiosystems for cancer theranostics: an overview of emerging trends and challenges.Nanomedicine (London, England) · 2025Review
- Impact of targeting the platelet-activating factor and its receptor in cancer treatment.Military Medical Research · 2025Review
- Platelet-activating factor (PAF) promotes immunosuppressive neutrophil differentiation within tumors.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- First-Row Transition Metal Complexes Incorporating the 2-(2'-pyridyl)quinoxaline Ligand (pqx), as Potent Inflammatory Mediators: Cytotoxic Properties and Biological Activities against the Platelet-Activating Factor (PAF) and Thrombin.Molecules (Basel, Switzerland) · 2023Article
- Tin(II) and Tin(IV) Complexes Incorporating the Oxygen Tripodal Ligands [(Molecules (Basel, Switzerland) · 2023Article
- Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer Cells and Immune Cells.Frontiers in immunology · 2022Review
- UVB-Induced Microvesicle Particle Release and Its Effects on the Cutaneous Microenvironment.Frontiers in immunology · 2022Review
- New Insights Into the Pathologic Roles of the Platelet-Activating Factor System.Frontiers in endocrinology · 2021Review
- Platelet-Activating Factor-Receptor Signaling Mediates Targeted Therapies-Induced Microvesicle Particles Release in Lung Cancer Cells.International journal of molecular sciences · 2020Article
- Transition Metal-Mediated C-C Single Bond Cleavage: Making the Cut in Total Synthesis.Angewandte Chemie (International ed. in English) · 2020Review
- Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.Molecules (Basel, Switzerland) · 2019Review
- The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment.Advances in nutrition (Bethesda, Md.) · 2019Review
- Gemcitabine Induces Microvesicle Particle Release in a Platelet-Activating Factor-Receptor-Dependent Manner via Modulation of the MAPK Pathway in Pancreatic Cancer Cells.International journal of molecular sciences · 2018Article
- Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy.Clinics (Sao Paulo, Brazil) · 2018Review
- Platelet-Activating Factor Receptor Ligands Protect Tumor Cells from Radiation-Induced Cell Death.Frontiers in oncology · 2018Article
- Oncogenic effects of PAFR ligands produced in tumours upon chemotherapy and radiotherapy.Nature reviews. Cancer · 2017Article
- Platelet-activating factor (PAF) receptor as a promising target for cancer cell repopulation after radiotherapy.Oncogenesis · 2017Article
- Implications of Aspirin for Melanoma Treatment: A Short Perspective.Journal of molecular genetics and medicine · 2017Article
- Modulation of Tumor-Associated Macrophages (TAM) Phenotype by Platelet-Activating Factor (PAF) Receptor.Journal of immunology research · 2017Article
- A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?Bioinorganic chemistry and applications · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma cells express the platelet-activating factor receptor (PAFR) and, thus, respond to PAF, a bioactive lipid produced by both tumour cells and those in the tumour microenvironment such as macrophages. Here, we show that treatment of a human melanoma SKmel37 cell line with cisplatin led to increased expression of PAFR and its accumulation. In the presence of exogenous PAF, melanoma cells were significantly more resistant to cisplatin-induced cell death. Inhibition of PAFR-dependent signalling pathways by a PAFR antagonist (WEB2086) showed chemosensitisation of melanoma cells in vitro. Nude mice were inoculated with SKmel37 cells and treated with cisplatin and WEB2086. Animals treated with both agents showed significantly decreased tumour growth compared to the control group and groups treated with only one agent. PAFR accumulation and signalling are part of a prosurvival program of melanoma cells, therefore constituting a promising target for combination therapy for melanomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.